Related Experiment Video
Updated: Nov 15, 2025
03:05
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
1.3K
Estimating the Odds of Ulcerative Colitis-Associated Pyoderma Gangrenosum: A Population-Based Case-Control Study
Khalaf Kridin1,2, Giovanni Damiani3,4,5, Ralf J Ludwig6
1Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany, dr_kridin@hotmail.com.
Dermatology (Basel, Switzerland)
|March 1, 2021
Summary
Ulcerative colitis (UC) significantly increases the risk of developing pyoderma gangrenosum (PG) by 15-fold. The highest risk for PG occurs within the first year after a UC diagnosis.
Area of Science:
- Gastroenterology
- Dermatology
- Epidemiology
Background:
- Ulcerative colitis (UC) is a known comorbidity of pyoderma gangrenosum (PG).
- The specific risk of developing PG following a UC diagnosis remains unclear.
- This study quantifies the association between UC and subsequent PG development.
Purpose of the Study:
- To estimate the magnitude of the association between UC and the subsequent occurrence of PG.
- To assess the odds of PG developing in individuals with a history of UC.
Main Methods:
- A population-based case-control study.
- Compared 302 PG patients with 1,497 matched controls for UC presence.
- Utilized logistic regression for univariate and multivariate analyses.
Main Results:
- Prevalence of UC was significantly higher in PG patients (7.3%) versus controls (0.5%).
- Individuals with UC had a 15-fold increased odds of developing PG (OR 14.62).
- The highest risk for PG occurred within the first year post-UC diagnosis (OR 35.50).
Conclusions:
- UC substantially increases the odds of developing PG by approximately 15-fold.
- The risk of PG is highest in the initial year after UC diagnosis.
- Advising UC patients to avoid PG precipitating factors is recommended.
Related Concept Videos
01:30Peptic Ulcer Disease I: Introduction
454
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
454
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
547
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
547
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
851
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
851
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
318
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
318
01:28Peptic Ulcer Disease II: Pathophysiology
1.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.4K
01:17Chronic Bowel Disorders: Introduction
631
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
631